STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[6-K] Haleon plc American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Haleon plc announced the purchase and cancellation of 175,642 ordinary shares of of each as part of the second tranche of its share buyback programme announced on 31 July 2025. After settlement, Haleonregistered share capital stands at 8,970,696,108 ordinary shares of each, of which 3,880,205 are held as treasury shares, leaving 8,966,815,903 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided link and on the Company's investor website. This announcement relates solely to the executed tranche of the buyback programme and the resulting share capital figures.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Executed a small tranche of the announced buyback; share capital and voting figures updated.

Haleon completed the purchase and cancellation of 175,642 ordinary shares under the second tranche of its buyback programme. The transaction reduced issued shares and increased treasury share holdings to 3,880,205, leaving 8,966,815,903 shares with voting rights. The notice provides a trade breakdown link but contains no financial impact metrics such as cash spent relative to market cap or percentage of programme completed. Given the absolute size versus total issued shares, this tranche appears operationally routine rather than material to earnings or leverage.

TL;DR: Buyback executed and cancelled; updated voting share count for disclosure compliance.

The announcement documents compliance with disclosure rules by reporting the cancellation and the updated voting share count that determines shareholders' notification thresholds under the FCA rules. It also references the Market Abuse Regulation trade breakdown. The filing is procedural and ensures accurate public registers and transparency; it contains no commentary on intent, timing of further tranches, or funding source.

UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of August 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
        99.1
22 August 2025 - “Transaction in Own Shares”
 
 
 
 
99.1
 
 
Haleon plc: Transaction in own shares
 
22 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 175,642 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.
 
 
London Stock Exchange
CBOE (UK)/BXE
CBOE (UK)/CXE
Date of purchase:
21 August 2025
21 August 2025
21 August 2025
Number of Shares purchased:
175,642
-
-
Highest price paid per Share (p):
366.0000
-
-
Lowest price paid per Share (p):
365.1000
-
-
Volume weighted average price paid per Share (p):
365.6259
-
-
 
Following the settlement of the above, the Company's registered share capital is 8,970,696,108 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,966,815,903 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
 
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
 
http://www.rns-pdf.londonstockexchange.com/rns/3368W_1-2025-8-21.pdf
 
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
 
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
 
Enquiries
 
 
Investors
Media
 
Jo Russell  
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel     
+44 7552 484646
Victoria Durman
+44 7894 505730
Email: investor-relations@haleon.com
Email: corporate.media@haleon.com
 
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: August 22, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary
Haleon

NYSE:HLN

HLN Rankings

HLN Latest News

HLN Latest SEC Filings

HLN Stock Data

43.06B
4.45B
0.02%
12.85%
0.36%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United Kingdom
Weybridge